The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma
- 1 March 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Nuclear Medicine Communications
- Vol. 35 (3), 311-315
- https://doi.org/10.1097/mnm.0000000000000059
Abstract
Aim The aim of the study was to investigate the value of fluorine-18-fluorodeoxyglucose (18F-FDG)-PET/computed tomography (CT) in identifying diffuse bone marrow (BM) involvement in follicular lymphoma using semiquantitative assessment. Methods This is a retrospective analysis of 41 patients with grade 1–3a follicular lymphoma who underwent 18F-FDG-PET/CT, contrast-enhanced CT and bone marrow trephine biopsy (BMB) as part of staging. BM involvement on PET/CT was assessed by visual and semiquantitative analysis. Standardized uptake values (SUVmax) were measured at the sternum, at both iliac blades and at the T12 vertebra. An average of these four measurements was recorded as SUVav. The single highest overall SUVmax for the four bone sites, the SUVav and the ratios SUVav/mediastinal blood pool (MBP) and SUVav/liver were compared with the BMB result. Results Focal bone uptake was identified on 18F-FDG-PET/CT by visual analysis in six patients, including two cases in which the BMB was negative. Assessment of diffuse BM involvement on 18F-FDG-PET/CT by visual analysis had a sensitivity and specificity of 31 and 92%, respectively. Semiquantitative analysis resulted in an improved sensitivity and specificity of 58 and 96%, respectively, when using SUVav greater than or equal to 2 as the cutoff. Using the ratio SUVav/MBP greater than or equal to 1 the sensitivity of 18F-FDG-PET/CT to detect BM involvement improved to 83%. Conclusion Visual analysis is useful in determining focal bone involvement, whereas semiquantitative analysis using SUVav/MBP has a high sensitivity and specificity for predicting BM involvement in patients lacking focal bone lesions.Keywords
This publication has 19 references indexed in Scilit:
- Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the18F-fluoro-2-deoxyglucose positron emission tomography eraLeukemia & Lymphoma, 2011
- SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphomaBlood, 2011
- F-18 FDG PET for Evaluation of Bone Marrow Involvement in Non-Hodgkin LymphomaClinical Nuclear Medicine, 2011
- Radionuclide imaging of bone marrow disordersEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2010
- 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 PatientsJournal of Nuclear Medicine, 2009
- The usefulness of 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) and a comparison of 18F‐FDG‐pet with 67gallium scintigraphy in the evaluation of lymphomaCancer, 2007
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomasCancer, 2006
- Utility of FDG-PET scanning in lymphoma by WHO classificationBlood, 2003